

**COMPARATIVE STUDY OF  
CHEMOTHERAPEUTIC MODALITIES OF  
LYMPHOMA IN THE PEDIATRIC AGE GROUP**

**THESIS**

Submitted for Partial Fulfillment of the  
Master Degree in  
**PEDIATRICS**

Presented by

**Dalia Essam El-Said Ahmed**

M.B., B.Ch (Ain Shams University)

*Under Supervision Of:*

**PROF. DR. MONA HUSSEIN EL-SAMAHY**

Professor of Pediatrics  
Faculty of Medicine  
Ain Shams University

**PROF. DR. MOHSEN ABDEL-HAMED GADALLAH**

Professor of Community Medicine  
Faculty of Medicine  
Ain Shams University


**DR. NAGHAM MOHAMED SAMI EL-BEBLAWY**

Lecturer of Pediatrics  
Faculty of Medicine  
Ain Shams University

**FACULTY OF MEDICINE  
AIN SHAMS UNIVERSITY  
1998**







﴿وقل رب زدني علما﴾

صدق الله العظيم [طه ١١٤]



## ACKNOWLEDGMENT

*To the Almighty God, to Him, whose knowledge is beyond all knowledge. I kneel to express the very humble gratitude of one of His very humble subjects.*

*I am greatly indebted to **Professor Mona Hussein El-Samahy**, Professor of Pediatrics Department, Ain Shams University, for her encouragement, consistent guidance and honest supervision. She has been mostly generous and kindly helpful. She has spared no effort so that this thesis would see light.*

*I am also greatly overwhelmed by the constant help and assistance offered by **Professor Mohsen Abd Elhamed Gad-Allah**, Professor of Community Medicine. He has provided me with all available facilities to do the statistical part of this work.*

*I am sincerely thankful to **Dr. Nagham Mohamed Sami El-Beblawy**, Lecturer of Pediatrics, Ain Shams University, for her Continuous interest and the precious time she has given me throughout the course of this work.*


*Finally, I would like to convey my warmest gratitude to my patients and their families, my colleagues and secretary and computer staff of the Pediatric Hematology/Oncology clinic, Ain-Shams University, for their thankful cooperation.*





**To...**

*My Mother with  
Love and Affection...*



**To...**

*My beloved  
Husband...*

*Dalia*



# CONTENTS

|                                | Page |
|--------------------------------|------|
| • List of abbreviations        | i    |
| • List of tables               | iii  |
| • List of figures              | v    |
| • Introduction .....           | 1    |
| • Aim of the work .....        | 3    |
| • Review of Literature         |      |
| - Definition .....             | 4    |
| - Classification .....         | 8    |
| - Epidemiology .....           | 28   |
| - Etiology .....               | 35   |
| - Clinical presentation .....  | 47   |
| - Treatment .....              | 58   |
| - Complications .....          | 77   |
| - Prognosis .....              | 82   |
| • Subject and Methods .....    | 86   |
| • Results .....                | 90   |
| • Discussion .....             | 116  |
| • Summary and Conclusion ..... | 125  |
| • References .....             | 128  |
| • Arabic summary .....         | ---  |



## **LIST OF ABBREVIATIONS**

|                 |                                                                  |
|-----------------|------------------------------------------------------------------|
| <b>ABMT</b>     | Autologous bone marrow transplantation                           |
| <b>ABVD</b>     | Adriamycin, bleomycin, dacarbazine and vinblastine.              |
| <b>AILD</b>     | Angioimmunoblastic lymphadenopathy                               |
| <b>ALL</b>      | Acute lymphoblastic leukemia                                     |
| <b>B-CAVe</b>   | Bleomycin, lomustine (CCNU), doxorubicin, and vinblastine        |
| <b>BCVPP</b>    | BCNU, cyclophosphamide, vincristine, procarbazine and prednisone |
| <b>BL</b>       | Burkitt's lymphoma                                               |
| <b>CD</b>       | Cluster designation                                              |
| <b>CEP</b>      | Lomustine (CCNU), etoposide (VP-16) and prednisolone             |
| <b>CHOP</b>     | Cyclophosphamide, adriamycin, vincristine and prednisone         |
| <b>CLLs</b>     | Chronic lymphocytic leukemias                                    |
| <b>CNS</b>      | Central nervous system                                           |
| <b>COMP</b>     | Cyclophosphamide, vincristine, methotrexate and prednisone       |
| <b>COPP</b>     | Cyclophosphamide, vincristine, procarbazine and prednisone       |
| <b>CVPP</b>     | Cyclophosphamide, vinblastine, procarbazine and prednisone       |
| <b>EBV</b>      | Ebstein Barr Virus                                               |
| <b>GFL</b>      | Giant follicular lymphoma                                        |
| <b>H.D.</b>     | Hodgkin's disease                                                |
| <b>HTL-V</b>    | Human T-cell leukemia Virus type V                               |
| <b>HTLV III</b> | Human T-cell lymphotropic Virus type III                         |
| <b>IL-2R</b>    | Interleukin-2R receptor                                          |
| <b>IPSID</b>    | Immunoproliferative small intestinal disease                     |

|                                      |                                                                                                      |
|--------------------------------------|------------------------------------------------------------------------------------------------------|
| <b>K.S.</b>                          | Kaposi sarcoma                                                                                       |
| <b>LD</b>                            | Lymphocyte depletion                                                                                 |
| <b>LDH</b>                           | Lactate dehydrogenase                                                                                |
| <b>LP</b>                            | Lymphocyte predominance                                                                              |
| <b>LS</b>                            | Lymphosarcoma                                                                                        |
| <b>LSA<sub>2</sub>-L<sub>2</sub></b> | Cyclophosphamide, dauramycin, vincristine, prednisone, ara-C, 6-thioguanine, L-asparaginase and BCNU |
| <b>MC</b>                            | Mixed cellularity                                                                                    |
| <b>MOMP</b>                          | Nitrogen mustard, vincristine, methotrexate and prednisone                                           |
| <b>MOPP</b>                          | Mechlorethamine, vincristine, procarbazine, prednisone                                               |
| <b>NCI</b>                           | National Cancer Institute                                                                            |
| <b>NHL</b>                           | Non-Hodgkin's lymphoma                                                                               |
| <b>NS</b>                            | Nodular sclerosis                                                                                    |
| <b>OEPA</b>                          | Vincristine, etoposide, prednisone and adriamycin                                                    |
| <b>OPPA</b>                          | Vincristine, procarbazine, prednisone, and adriamycin                                                |
| <b>PBSC</b>                          | peripheral blood stem cell                                                                           |
| <b>RCS</b>                           | Reticulum cell sarcoma                                                                               |
| <b>RFS</b>                           | Relapse free survival                                                                                |
| <b>RS</b>                            | Reed-Sternberg cell                                                                                  |
| <b>SLE</b>                           | Systemic lupus erythromatosis                                                                        |
| <b>SNC</b>                           | Small non cleaved                                                                                    |
| <b>TDT</b>                           | Terminal deoxynucleotidyl transferase                                                                |
| <b>VEEP</b>                          | Vincristine, epirubicin, etoposide and prednisolone                                                  |

## LIST OF TABLES

| No. | Title                                                                                                                     | Page |
|-----|---------------------------------------------------------------------------------------------------------------------------|------|
| 1   | Rye histopathological classification of HD and their relative frequencies                                                 | 10   |
| 2   | The Rappaport histopathologic classification modified for childhood NHL, and correlation with immune markers.             | 15   |
| 3   | Six classifications of non-Hodgkin's lymphomas.                                                                           | 16   |
| 4   | NCI working formulation and its relation to the Rappaport classification of NHL.                                          | 20   |
| 5   | Leukocyte differentiation antigens.                                                                                       | 26   |
| 6   | Staging classification system for HD.                                                                                     | 49   |
| 7   | Histological classification, relative frequency of histologic types and correlation with anatomic site, in childhood NHL. | 50   |
| 8   | Staging system for childhood NHL.                                                                                         | 53   |
| 9   | Staging of Burkitt's lymphoma.                                                                                            | 54   |
| 10  | Chronological flow of major concepts and events influencing the treatment evolution of Hodgkin's disease.                 | 60   |
| 11  | MOPP and ABVD regimens.                                                                                                   | 63   |
| 12  | Regimens in use for treatment of childhood NHL.                                                                           | 72   |
| 13  | Frequency distribution of childhood lymphoma/year                                                                         | 98   |
| 14  | Age distribution of childhood lymphoma.                                                                                   | 100  |
| 15  | Sex distribution of childhood lymphoma.                                                                                   | 100  |
| 16  | Seasonal distribution of childhood lymphoma.                                                                              | 100  |
| 17  | Clinical presentation of Hodgkin's disease (HD), non Hodgkin's lymphoma (NHL) and leukemic transformation (LT).           | 103  |
| 18  | Staging of NHL according to Murphy's staging system and HD according to Ann Arbor staging system.                         | 104  |

|    |                                                                        |     |
|----|------------------------------------------------------------------------|-----|
| 19 | Hematological finding in childhood lymphoma.                           | 106 |
| 20 | Histopathological typing of HD.                                        | 106 |
| 21 | Histopathological typing of NHL according to working formulation (SF). | 106 |
| 22 | Chemotherapeutic regimens in childhood lymphoma                        |     |
| 23 | Response of cases of HD to therapy.                                    |     |
| 24 | Characteristics of cases of HD relation to response to therapy.        |     |
| 25 | Response of cases of NHL to therapy.                                   |     |
| 26 | Characteristics of cases of NHL relation to response to therapy.       |     |
| 27 | Relapse rate in childhood lymphoma.                                    |     |
| 28 | Characteristics of cases of HD relation to relapse.                    |     |
| 29 | Characteristics of cases of NHL relation to relapse.                   |     |
| 30 | Death rate in childhood lymphoma.                                      |     |
| 31 | characteristics of cases of HD relation to death.                      |     |
| 32 | Characteristics of cases of NHL relation to death.                     |     |
| 33 | 5 years survival in childhood lymphoma.                                |     |